Gufic Biosciences Ltd
GUFICBIO
Company Profile
Business description
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
Contact
SM House, 11 Sahakar Road
1st to 4th Floor
Vile Parle (East)
MumbaiMH400 057
INDT: +91 2267261000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,926
Stocks News & Analysis
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,296.00 | 42.30 | -0.45% |
| CAC 40 | 8,188.59 | 111.59 | 1.38% |
| DAX 40 | 24,272.19 | 90.82 | 0.38% |
| Dow JONES (US) | 45,952.24 | 301.07 | -0.65% |
| FTSE 100 | 9,436.09 | 11.34 | 0.12% |
| HKSE | 25,514.15 | 374.36 | -1.45% |
| NASDAQ | 22,562.54 | 107.54 | -0.47% |
| Nikkei 225 | 47,827.31 | 450.43 | -0.93% |
| NZX 50 Index | 13,283.29 | 105.81 | -0.79% |
| S&P 500 | 6,629.07 | 41.99 | -0.63% |
| S&P/ASX 200 | 8,998.00 | 32.00 | -0.35% |
| SSE Composite Index | 3,883.81 | 32.41 | -0.83% |